Irinocan 40/Irinocan 100 Indications/Uses

Irinotecan Hydrochloride Trihydrate Injection 20 mg/mL is indicated for the treatment of patients with advanced colorectal cancer: In combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease.
As a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.
Irinotecan Hydrochloride Trihydrate Injection 20 mg/mL in combination with Cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR) expressing, KRAS wild-type metastatic colorectal cancer, who had not received prior treatment for metastatic disease or after failure of Irinotecan including cytotoxic therapy.
Irinotecan Hydrochloride Trihydrate Injection 20 mg/mL in combination with 5-fluorouracil, folinic acid and Bevacizumab is indicated for first line treatment of patients with metastatic carcinoma of the colon or rectum.
Irinotecan Hydrochloride Trihydrate Injection 20 mg/mL in combination with Capecitabine with or without Bevacizumab is indicated for first-line treatment of patients with metastatic colorectal carcinoma.